David Wong's Biography

• Home
• |
• Register
• |
• Posters
• |
• Exhibition
• |
• Venue
• |
• Short Courses
  • Training Courses
• |
• Posters
• |
• Testimonials
• |
• Media
• |

Saliva-based Exosomes for Liquid Biopsies

Monday, 23 March 2015 at 09:30

Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com

Constitutive activation of epithelial growth factor receptor (EGFR) is prevalent in epithelial cancers, particularly in non-small-cell lung carcinoma (NSCLC). EGFR mutation predicts sensitivity to EGFR-targeted therapy and mutation detection is mainly based on tissue biopsy, which is invasive, expensive and time-consuming. Non-invasive, real-time, point-of-care, inexpensive detection and monitoring of EGFR mutations in NSCLC patients is highly desirable. We developed a novel core technology, Electric Field-Induced Release and Measurement (EFIRM), relying on a multiplexible electrochemical sensor that can detect EGFR mutations directly from body fluids. EFIRM for EGFR mutation detection was established in vitro, and correlated with tumor size from xenografted mice. In clinical application, we demonstrated that EFIRM can detect EGFR mutations from saliva and serum of 22 NSCLC patients. And finally, a blinded test was performed on saliva from 40 NSCLC patient saliva samples. The receiver operating characteristic analysis indicated that EFIRM detected the exon 19 deletion with an area under the curve (AUC) of 0.94 and the L858R mutation with an AUC of 0.96. Our data indicate that EFIRM is effective, accurate, rapid, user-friendly, and cost effective for the detection of EGFR mutations in saliva of NSCLC patients. We termed this SAliva-Based EGFR (SABER) Mutation Detection for detection and monitoring EGFR mutations in saliva of NSCLC patients.

Challenges in the Deployment of Saliva in Diagnostics Development

Monday, 23 March 2015 at 14:30

Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com

Extracellular RNAs (exRNAs) in biofluids have sparked considerable interests in their use as disease-specific diagnostic and prognostic biomarkers. In the last decade, it has been demonstrated the potential use of salivary RNA for detecting various local and systemic diseases such as oral cancer, Sjögren syndrome, pancreatic cancer and breast cancer. The ability of sequence-characterized salivary exRNA by using next-generation sequencing can further strengthen the advantages of using saliva as a clinical diagnostic biofluid for biomarker discovery.  Compared with other bodily fluids, saliva can be collected easily and noninvasively. However, low RNA abundance, small sample volumes, high fragmentation of RNA and lots of bacterial contents create challenges for downstream RNA sequencing assays.

Saliva-based Exosomes for Liquid Biopsies

Monday, 23 March 2015 at 09:30

Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com

Constitutive activation of epithelial growth factor receptor (EGFR) is prevalent in epithelial cancers, particularly in non-small-cell lung carcinoma (NSCLC). EGFR mutation predicts sensitivity to EGFR-targeted therapy and mutation detection is mainly based on tissue biopsy, which is invasive, expensive and time-consuming. Non-invasive, real-time, point-of-care, inexpensive detection and monitoring of EGFR mutations in NSCLC patients is highly desirable. We developed a novel core technology, Electric Field-Induced Release and Measurement (EFIRM), relying on a multiplexible electrochemical sensor that can detect EGFR mutations directly from body fluids. EFIRM for EGFR mutation detection was established in vitro, and correlated with tumor size from xenografted mice. In clinical application, we demonstrated that EFIRM can detect EGFR mutations from saliva and serum of 22 NSCLC patients. And finally, a blinded test was performed on saliva from 40 NSCLC patient saliva samples. The receiver operating characteristic analysis indicated that EFIRM detected the exon 19 deletion with an area under the curve (AUC) of 0.94 and the L858R mutation with an AUC of 0.96. Our data indicate that EFIRM is effective, accurate, rapid, user-friendly, and cost effective for the detection of EGFR mutations in saliva of NSCLC patients. We termed this SAliva-Based EGFR (SABER) Mutation Detection for detection and monitoring EGFR mutations in saliva of NSCLC patients.

Saliva-based Exosomes for Liquid Biopsies

Monday, 23 March 2015 at 09:30

Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com

Constitutive activation of epithelial growth factor receptor (EGFR) is prevalent in epithelial cancers, particularly in non-small-cell lung carcinoma (NSCLC). EGFR mutation predicts sensitivity to EGFR-targeted therapy and mutation detection is mainly based on tissue biopsy, which is invasive, expensive and time-consuming. Non-invasive, real-time, point-of-care, inexpensive detection and monitoring of EGFR mutations in NSCLC patients is highly desirable. We developed a novel core technology, Electric Field-Induced Release and Measurement (EFIRM), relying on a multiplexible electrochemical sensor that can detect EGFR mutations directly from body fluids. EFIRM for EGFR mutation detection was established in vitro, and correlated with tumor size from xenografted mice. In clinical application, we demonstrated that EFIRM can detect EGFR mutations from saliva and serum of 22 NSCLC patients. And finally, a blinded test was performed on saliva from 40 NSCLC patient saliva samples. The receiver operating characteristic analysis indicated that EFIRM detected the exon 19 deletion with an area under the curve (AUC) of 0.94 and the L858R mutation with an AUC of 0.96. Our data indicate that EFIRM is effective, accurate, rapid, user-friendly, and cost effective for the detection of EGFR mutations in saliva of NSCLC patients. We termed this SAliva-Based EGFR (SABER) Mutation Detection for detection and monitoring EGFR mutations in saliva of NSCLC patients.